Home/ Stocks/ CLYM

Climb Bio, Inc. Common Stock

CLYM XNAS

$10.29 +1.47 (+16.57%) ▲ 15-min delayed

Open

$9.05

High

$10.33

Low

$8.84

Volume

1.14M

Market Cap

$604.42M

About Climb Bio, Inc. Common Stock

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 29 Website →

Related Market News

No specific coverage for CLYM yet. Check out our latest market news or earnings calendar.

Get CLYM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Climb Bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.